{ "schema_version": "rangoon.article.v1", "id": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/", "url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/", "markdown_url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/index.md", "json_url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/index.json", "title": "Boltz-2 put binding-affinity prediction beside structure prediction", "summary": "The Boltz team introduced Boltz-2 on June 6, 2025, reporting an open model for joint biomolecular structure and binding-affinity prediction.", "language": "en", "author": { "name": "Rangoon Editorial", "url": "https://rangoon.ai/insights/editorial/" }, "publisher": { "name": "Rangoon", "maintainer": "Hypler", "url": "https://rangoon.ai/" }, "format": "News analysis", "topic": { "slug": "models", "label": "Models", "url": "https://rangoon.ai/insights/topics/models/" }, "tags": [ { "slug": "protein-science", "label": "protein science", "url": "https://rangoon.ai/insights/tags/protein-science/" }, { "slug": "open-models", "label": "open models", "url": "https://rangoon.ai/insights/tags/open-models/" }, { "slug": "research-ai", "label": "research AI", "url": "https://rangoon.ai/insights/tags/research-ai/" }, { "slug": "model-evaluation", "label": "model evaluation", "url": "https://rangoon.ai/insights/tags/model-evaluation/" } ], "dates": { "published": "2026-10-23", "updated": "2026-10-23", "event": "2025-06-06" }, "event_source_id": 1, "retrospective": true, "reading_minutes": 3, "takeaways": [ "Boltz-2 joined a structure prediction task with a binding-affinity prediction task.", "Affinity evaluation needs target, ligand, assay and data-split context.", "In-silico ranking cannot establish potency, selectivity, safety or therapeutic value." ], "source_note": "Historical reporting: the Boltz team announced Boltz-2 on June 6, 2025 and released its technical report. Predicted affinity and reported benchmark scores are not experimental binding confirmation or clinical guidance.", "sources": [ { "id": 1, "title": "Boltz: Introducing Boltz-2", "url": "https://boltz.bio/boltz2", "published": "2025-06-06" }, { "id": 2, "title": "Boltz project repository", "url": "https://github.com/jwohlwend/boltz", "published": "2025-06-06" } ], "image": { "url": "https://rangoon.ai/assets/editorial/archive-boltz2-binding-affinity-2025-diagram-v1.webp", "thumbnail_url": "https://rangoon.ai/assets/editorial/archive-boltz2-binding-affinity-2025-diagram-v1-thumb.webp", "alt": "Original research review diagram: Binding prediction evidence ledger. Concepts: Target, Ligand, Structure, Affinity score, Assay, Baseline, Result. Editorial checklist, not vendor test results or an official legal determination.", "type": "original-diagram", "caption": "Binding prediction evidence ledger. Original Rangoon explanatory diagram: concepts for editorial review, not measured results, an official legal determination, vendor interface or event photograph.", "credit": "Rangoon / Hypler", "source_url": "https://rangoon.ai/brand/", "rights_url": "https://rangoon.ai/terms/#media-use", "rights_note": "Hypler artwork permissions do not grant rights to third-party marks or imply endorsement." }, "sections": [ { "id": "event-record", "url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/#event-record", "heading": "The June release expanded the target beyond structure", "paragraphs": [ "The Boltz team announced Boltz-2 on June 6, 2025, describing an open biomolecular foundation model intended to predict both complex structures and binding affinities. This matters because a plausible complex geometry and a useful affinity estimate are different scientific targets. The release and technical materials support inspection of the authors’ method and reported comparisons. They do not establish that a predicted interaction binds in an assay, that a ranked molecule is selective, or that a computational result has a medical implication. Those require their own experimental and regulatory evidence." ], "bullets": [], "source_ids": [ 1, 2 ] }, { "id": "research-record", "url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/#research-record", "heading": "Joint outputs should be judged against their separate observables", "paragraphs": [ "Structure and affinity labels arise from different measurements and sources of uncertainty. A model can produce a geometrically plausible pose yet mis-rank a series when solvation, flexibility, assay conditions or data bias matter. Conversely, an affinity score may be useful for ranking within a defined set without proving a detailed mechanism. Evaluation must name the target family, ligand representation, split strategy, assay type, metric and baseline. A headline comparison with a physics-based method belongs to the stated benchmark conditions, not to every protein-ligand pair a user may submit." ], "bullets": [], "source_ids": [ 1, 2 ] }, { "id": "interpretation-boundary", "url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/#interpretation-boundary", "heading": "Predicted binding is not a drug-development conclusion", "paragraphs": [ "Binding is only one part of a compound-development decision. Potency, selectivity, permeability, metabolism, toxicity, formulation and clinical benefit are distinct questions. A model output should be reported as a computational prioritization signal, with model revision and input provenance attached, rather than as proof of efficacy. This article offers no molecule-design instructions or medical advice. It distinguishes model prediction from laboratory evidence because a single affinity number can otherwise be misread as a broad statement about a candidate’s value or safety." ], "bullets": [], "source_ids": [ 1, 2 ] }, { "id": "study-design", "url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/#study-design", "heading": "Ranking studies need prospective and negative controls", "paragraphs": [ "To evaluate a model for a new target, hold out a prospective set before scoring and compare the model’s ranked list with a transparent baseline. Include known non-binders or decoys where appropriate, then record assay conditions, replicate variability and failures to obtain material. Test whether a score remains useful across chemical series rather than only within one familiar scaffold. If a score triggers synthesis, preserve the decision threshold and all tested candidates so later analysis can assess enrichment rather than only count an isolated successful hit." ], "bullets": [], "source_ids": [ 1, 2 ] }, { "id": "historical-analysis", "url": "https://rangoon.ai/insights/archive-boltz2-binding-affinity-2025/#historical-analysis", "heading": "Analysis: co-folding claims should preserve the assay boundary", "paragraphs": [ "Boltz-2 is a good archival example of an AI research release that spans two related but non-interchangeable molecular outputs. The reporting discipline is to keep pose, affinity and downstream biological claims on separate ledgers. The release calls out protein-small-molecule affinity prediction; that named output must be evaluated with a target, ligand set and assay definition rather than borrowed from a structure-only benchmark. Prospective measurements remain the evidence that turns an in-silico ordering into a scientifically useful ranking for a defined target series.", "A binding-affinity model should earn confidence through prospective, measured rankings with explicit assay conditions, not through a structure image that makes a modeled complex appear experimentally observed." ], "bullets": [], "source_ids": [ 1, 2 ] } ], "project_context": null, "related_links": [], "permissions_url": "https://rangoon.ai/permissions.txt", "content_hash": "sha256:711a68165e534c71a284d255b125e3ea7f94af5e7d5461fdab254403282d04fe" }